Study on the relationship between <i>TLR2</i> and <i>TLR4</i> polymorphism and CpG island methylation and anti-tuberculosis drug-induced liver injury

LI Yue; MA Shuo; LIU Yue; TANG Qinyan; GUO Yu; LIU Yang; PEI Shengfei; FENG Fumin

doi:10.16462/j.cnki.zhjbkz.2025.02.015

Volume 29 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(2): 217-223

LI Yue, MA Shuo, LIU Yue, TANG Qinyan, GUO Yu, LIU Yang, PEI Shengfei, FENG Fumin. Study on the relationship between TLR2 and TLR4 polymorphism and CpG island methylation and anti-tuberculosis drug-induced liver injury[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(2): 217-223. doi: 10.16462/j.cnki.zhjbkz.2025.02.015

Citation:

LI Yue, MA Shuo, LIU Yue, TANG Qinyan, GUO Yu, LIU Yang, PEI Shengfei, FENG Fumin. Study on the relationship between TLR2 and TLR4 polymorphism and CpG island methylation and anti-tuberculosis drug-induced liver injury[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(2): 217-223. doi: 10.16462/j.cnki.zhjbkz.2025.02.015

Citation:

PDF( 2087 KB)

Study on the relationship between TLR2 and TLR4 polymorphism and CpG island methylation and anti-tuberculosis drug-induced liver injury

doi: 10.16462/j.cnki.zhjbkz.2025.02.015

LI Yue^{1, 2},
MA Shuo¹,
LIU Yue¹,
TANG Qinyan¹,
GUO Yu¹,
LIU Yang¹,
PEI Shengfei¹,
FENG Fumin^{1
,
,}

1.
School of Public Health, North China University of Science and Technology, Hebei Provincial Collaborative Innovation Center for Occupational Health and Safety, Tangshan 063210, China
2.
Department of Preventive Health Care, Kailuan General Hospital, Tangshan 063000, China

Funds:

National Natural Science Foundation of China 81041096

More Information

Corresponding author: FENG Fumin, E-mail: fm_feng@sina.com
Received Date: 2023-11-20
Rev Recd Date: 2024-04-09

Available Online: 2025-03-08

Publish Date: 2025-02-10

Abstract

Abstract

Objective To investigate the relationship between single nucleotide polymorphisms rs7656411, rs3804099, rs1927914, rs1927911 in Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) genes, as well as CpG island methylation in the TLR2 gene promoter region, and anti-tuberculosis drug-induced liver injury (ADLI). Methods From July 2019 to March 2022, 322 tuberculosis patients with ADLI and 322 tuberculosis patients without ADLI were selected and matched 1∶1 based on gender, age, and treatment regimen. Gene polymorphisms and methylation patterns were detected using methylation-specific polymerase chain reaction(PCR) and PCR-restriction fragment length polymorphism(PCR-RFLP) technique. Results The wild-type genotype of TLR2 gene rs3804099 site (OR=0.55, 95% CI: 0.31-0.96) and CpG island methylation rate (OR=1.81, 95% CI: 1.07-3.06) were significantly higher in ADLI patients than in the control group (P < 0.05), with no statistical difference in the genotype frequency of other polymorphic sites between the two groups. Multivariate analysis showed that the wild-type TT of TLR2 gene rs3804099 site was associated with the progression of ADLI, and the wild-type TT may be a protective factor for ADLI OR=0.53 (95% CI: 0.38-0.75). In addition, high methylation of CpG island in TLR2 gene was independently associated with the risk of ADLI, with adjusted OR of 1.86 (95% CI: 1.05-3.28). The interaction between the mutation of rs3804099 site and high methylation of CpG island increased the risk of ADLI, being 2.12 times that of the control group (OR=2.12, 95% CI: 1.36-3.29). Conclusions There is an association between TLR2 gene polymorphism and CpG island methylation and ADLI. The interaction between CpG island methylation in the TLR2 gene promoter region and the gene polymorphism at rs3804099 is associated with a high risk of ADLI.
- Gene polymorphisms,
- Anti-tuberculosis drugs,
- Liver injury,
- Methylation

FullText(HTML)

References(22)

References

[1]	李雨珊, 陆霓虹. 抗结核药物性肝损伤分子机制研究进展[J]. 中国医药科学, 2023, 13(14): 20-24. DOI: 10.20116/j.issn2095-0616.2023.14.04. Li YS, Lu NH. Research progress in the molecular mechanism of anti-tuberculosis drug-induced liver injury[J]. China Medicine and Pharmacy, 2023, 13(14): 20-24. DOI: 10.20116/j.issn2095-0616.2023.14.04.
[2]	Abbaspour F, Hasannezhad M, Khalili H, et al. Managing hepatotoxicity caused by anti-tuberculosis drugs: a comparative study of approaches[J]. Arch Iran Med, 2024, 27(3): 122-126. DOI: 10.34172/aim.2024.19.
[3]	Akkahadsee P, Sawangjit R, Phumart P, et al. Systematic review and network Meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury[J]. Sci Rep, 2023, 13(1): 19880. DOI: 10.1038/s41598-023-46565-3.
[4]	Kumar S, Duan QH, Wu RX, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113869. DOI: 10.1016/j.addr.2021.113869.
[5]	Xu LY, Liu W, Bai FX, et al. Hepatic macrophage as a key player in fatty liver disease[J]. Front Immunol, 2021, 12: 708978. DOI: 10.3389/fimmu.2021.708978.
[6]	Chen DN, Xie WM, Lu YK, et al. Gene polymorphisms of TLR2 and TLR3 in HBV clearance and HBV-related hepatocellular carcinoma in a Chinese male population[J]. Int J Biol Markers, 2017, 32(2): e195-e201. DOI: 10.5301/jbm.5000238.
[7]	Neamatallah M, El-Bendary M, Elalfy H, et al. Impact of toll-like receptors 2( TLR2 ) and TLR4 gene variations on HCV susceptibility, response to treatment and development of hepatocellular carcinoma in cirrhotic HCV patients[J]. Immunol Invest, 2020, 49(4): 462-476. DOI: 10.1080/08820139.2019.1673772.
[8]	Elbrolosy AM, Elabd NS, ElGedawy GA, et al. Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients[J]. Clin Exp Med, 2023, 23(1): 117-129. DOI: 10.1007/s10238-022-00792-6.
[9]	Shi GJ, Wang CX, Zhang P, et al. Donor polymorphisms of toll-like receptor 4 rs1927914 associated with the risk of hepatocellular carcinoma recurrence following liver transplantation[J]. Arch Med Res, 2017, 48(6): 553-560. DOI: 10.1016/j.arcmed.2017.11.011.
[10]	Wu DX, Li YH, Ren Q, et al. TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury[J]. Sci Rep, 2021, 11(1): 17423. DOI: 10.1038/s41598-021-96869-5.
[11]	许登高, 周扬, 潘庆杰. 哺乳动物CpG岛甲基化研究进展[J]. 青岛农业大学学报(自然科学版), 2012, 29(4): 252-260, 266. DOI: 10.3969/J.ISSN.1674-148X.2012.04.004. Xu DG, Zhou Y, Pan QJ. The methylation of CpG island in mammals[J]. Journal of Qingdao Agricultural University (Natural Science), 2012, 29(4): 252-260, 266. DOI: 10.3969/J.ISSN.1674-148X.2012.04.004.
[12]	Zhang D, Hao JQ, Hou RL, et al. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients[J]. J Clin Pharm Ther, 2020, 45(3): 561-569. DOI: 10.1111/jcpt.13097.
[13]	Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol, 1990, 11(2): 272-276. DOI: 10.1016/0168-8278(90)90124-a.
[14]	Andersson T, Alfredsson L, Källberg H, et al. Calculating measures of biological interaction[J]. Eur J Epidemiol, 2005, 20(7): 575-579. DOI: 10.1007/s10654-005-7835-x.
[15]	Wu XZ, Dayanand KK, Thylur Puttalingaiah R, et al. Different TLR signaling pathways drive pathology in experimental cerebral malaria vs. malaria-driven liver and lung pathology[J]. J Leukoc Biol, 2023, 113(5): 471-488. DOI: 10.1093/jleuko/qiad021.
[16]	Brennan JJ, Gilmore TD. Evolutionary origins of toll-like receptor signaling[J]. Mol Biol Evol, 2018, 35(7): 1576-1587. DOI: 10.1093/molbev/msy050.
[17]	Xie JJ, Jiang SY, Shi MM, et al. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility[J]. BMC Cancer, 2012, 12: 57. DOI: 10.1186/1471-2407-12-57.
[18]	Elbrolosy AM, Elabd NS, ElGedawy GA, et al. Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients[J]. Clin Exp Med, 2023, 23(1): 117-129. DOI: 10.1007/s10238-022-00792-6.
[19]	Deaton AM, Bird A. CpG islands and the regulation of transcription[J]. Genes Dev, 2011, 25(10): 1010-1022. DOI: 10.1101/gad.2037511.
[20]	Harahap WA, Sudji IR, Nindrea RD. BRCA1 promoter methylation and clinicopathological characteristics in sporadic breast cancer patients in Indonesia[J]. Asian Pac J Cancer Prev, 2018, 19(9): 2643-2649. DOI: 10.22034/APJCP.2018.19.9.2643.
[21]	Shen LH, Zhang B, Sun SF, et al. Methylation of cytochrome p450 2E1 promoter induced by low dosage of isoniazid[J]. Environ Toxicol Pharmacol, 2013, 36(1): 149-151. DOI: 10.1016/j.etap.2013.03.016.
[22]	Zhang B, Sun SF, Shen LH, et al. DNA methylation in the rat livers induced by low dosage isoniazid treatment[J]. Environ Toxicol Pharmacol, 2011, 32(3): 486-490. DOI: 10.1016/j.etap.2011.07.001.